RD06-04 CART Cell Therapy(Nanjing Bioheng Biotech)

N/A

Report date: 2024/08/13 20:00:09

Base Information

Drug NameRD06-04 CART Cell Therapy(Nanjing Bioheng Biotech)
Drug Alias NameTargeted CD19CAR-T Therapy(Nanjing Bioheng Biotech)CAR-T Cell therapyTargeting CD19(Nanjing Bioheng Biotech)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsT lymphocyte replacements
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsSclerosisAutoimmune DiseasesScleroderma, Systemic +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesNanjing Bioheng Biotech Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNanjing Bioheng Biotech Co LtdPeking University People'S Hospital
Inactive CompaniesN/A
Active IndicationsAutoimmune DiseasesScleroderma, SystemicLupus Erythematosus, Systemic +[6] 
Inactive IndicationsSclerosisNeuromyelitis OpticaMultiple Sclerosis

Other Information

ATC CodeN/A
Related LinksN/A